Cyclin-dependent kinase inhibition with roscovitine: Neuroprotection in acute ischemic stroke

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 327-332

  Timsit, S ^a   Menn, B ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; ROSCOVITINE;

ARTICLE; BLOOD CLOT LYSIS; BRAIN CELL; BRAIN ISCHEMIA; CELL DEATH; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; HUMAN; ISOMER; NONHUMAN; PRIORITY JOURNAL; STROKE;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; PURINES; STROKE;

EID: 84855944688     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.312     Document Type: Article

References (40)

1. Feigin, V.L., Lawes, C.M., Bennett, D.A. & Anderson, C.S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2, 43-53 (2003). (Pubitemid 37443343)
2. Kleindorfer, D., Lindsell, C.J., Brass, L., Koroshetz, W. & Broderick, J.P. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 39, 924-928 (2008). (Pubitemid 351619542)
3. Sacco, R.L., Chong, J.Y., Prabhakaran, S. & Elkind, M.S. Experimental treatments for acute ischaemic stroke. Lancet 369, 331-341 (2007). (Pubitemid 46136492)
4. Astrup, J., Symon, L., Branston, N.M. & Lassen, N.A. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke. 8, 51-57 (1977).
5. Dirnagl, U., Iadecola, C. & Moskowitz, M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22, 391-397 (1999). (Pubitemid 29453643)
6. Heintz, N. Cell death and the cell cycle: a relationship between transformation and neurodegeneration? Trends Biochem. Sci. 18, 157-159 (1993). (Pubitemid 23142567)
7. Park, D.S., Obeidat, A., Giovanni, A. & Greene, L.A. Cell cycle regulator in neuronal death evoked by excitotoxic stress: implications for neurodegeneration and its treatment. Neurobiol. Aging 21, 771-781 (2000).
8. Sherr, C.J. Mammalian G1 cyclins. Cell 73, 1059-1065 (1993).
9. Dhavan, R. & Tsai, L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759 (2001).
10. Timsit, S. & Menn, B. Cerebral ischemia, cell cycle elements and Cdk5. Biotechnol. J. 2, 958-966 (2007). (Pubitemid 47377103)
11. Rashidian, J., Iyirhiaro, G.O. & Park, D.S. Cell cycle machinery and stroke. Biochim. Biophys. Acta 1772, 484-493 (2007). (Pubitemid 46400387)
12. Knockaert, M., Greengard, P. & Meijer, L. Pharmacological inhibitors of cyclin dependent kinases. Trends Pharmacol. Sci. 23, 417-425 (2002). (Pubitemid 35247771)
13. O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H. & Howells, D.W. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467-477 (2006). (Pubitemid 43358067)
14. Fischer, M. et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40, 2244-2250 (2009).
15. S.T.A.I.R. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758 (1999).
16. Shuaib, A. et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357, 562-571 (2007). (Pubitemid 47236281)
17. Savitz, S.I. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 205, 20-25 (2007). (Pubitemid 46621180)
18. Philip, M., Benatar, M., Fisher, M. & Savitz, S.I. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Stroke. 40, 577-581 (2009).
19. Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208-31219 (2005). (Pubitemid 41291858)
20. Menn, B., Bach, S., Blevins, T.L., Campbell, M., Meijer, L. & Timsit, S. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS ONE 5, e12117 (2010).
21. Wen, Y. et al. Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473-483 (2007). (Pubitemid 46400382)
22. Zhang, Q. et al. Cell cycle inhibition attenuates microglial proliferation and production of IL-1beta, MIP-1alpha, and NO after focal cerebral ischemia in the rat. Glia 57, 908-920 (2009).
23. Hilton, G.D., Stoica, B.A., Byrnes, K.R. & Faden, A.I. Roscovitine reduces neuronal loss, glial activation, and neurologic deficits after brain trauma. J. Cereb. Blood Flow Metab. 28, 1845-1859 (2008).
24. Zhang, M., Li, J., Chakrabarty, P., Bu, B. & Vincent, I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 165, 843-853 (2004). (Pubitemid 39129292)
25. Vita, M. et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur. J. Pharm. Sci. 25, 91-103 (2005). (Pubitemid 40602199)
26. Hsieh, W.S. et al. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin. Cancer Res. 15, 1435-1442 (2009).
27. Aldoss, I.T., Tashi, T. & Ganti, A.K. Seliciclib in malignancies. Expert Opin. Investig. Drugs 18, 1957-1965 (2009).
28. Smith, S.W. Chiral toxicology: it's the same thing.only different. Toxicol. Sci. 110, 4-30 (2009).
29. Sakakibara, Y., Mitha, A.P., Ayoub, I.A., Ogilvy, C.S. & Maynard, K.I. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res. 931, 68-73 (2002). (Pubitemid 34230532)
30. Calabrese, E.J. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Crit. Rev. Toxicol. 38, 557-577 (2008). (Pubitemid 351962352)
31. Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566 (2009).
32. Le Tourneau, C. et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur. J. Cancer 46, 3243-3250 (2010).
33. Wood, H. Stroke: S-roscovitine-a potential neuroprotectant for stroke. Nat. Rev. Neurol. 6, 527 (2010).
34. Chavez, J.C., Hurko, O., Barone, F.C. & Feuerstein, G.Z. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke. 40, e558-e563 (2009).
35. Hacke, W. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317-1329 (2008).
36. Warach, S. et al. Effect of the Glycine Antagonist Gavestinel on cerebral infarcts in acute stroke patients, a randomized placebo-controlled trial: The GAIN MRI Substudy. Cerebrovasc. Dis. 21, 106-111 (2006). (Pubitemid 43110319)
37. Warach, S. et al. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Ann. Neurol. 48, 713-722 (2000).
38. Singhal, A.B. et al. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke. 36, 797-802 (2005).
39. De Georgia, M.A. et al. Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling. Neurology 63, 312-317 (2004). (Pubitemid 38971132)
40. Donnan, G.A., Baron, J.C., Ma, H. & Davis, S.M. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 8, 261-269 (2009).